Please assess the completion status of the following clinical trial:

Trial Title: A Pharmacokinetics, Safety and Efficacy Study of Tafenoquine (TQ) in Pediatric Subjects With Plasmodium Vivax (P. Vivax) Malaria

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Subject is \>=2 years to \<16 years of age at the time of signing of the assent and/or informed consent. An additional cohort of subjects aged \>=6 months to \<2 years may be recruited following the first interim analysis.~* The subject has a positive malarial smear for P. vivax.~* The subject has a history of fever within 48 hours prior to enrollment.~* The subject has a glucose 6-phosphate dehydrogenase (G6PD) value (measured by a quantitative spectrophotometric phenotype assay) \>=70% of the site median value for G6PD normal adult males.~* The subject has a screening Hb value \>=8 gram per decilitre (g/dL).~* The subject has a body weight \>=5 kg.~* Males and females are eligible to enter the study. A female is eligible to enter and participate in this study if she is non-pregnant, non-lactating and if she is of: Non-childbearing potential (i.e., premenstrual); or Child-bearing potential, has a negative pregnancy test at screening, and agrees to comply with one of the following during the treatment stage of the study and for a period of 90 days after stopping study medication: Complete abstinence from intercourse for 2 weeks prior to administration of study medication, throughout the study and for a period of 90 days after stopping study medication; Use of combined oral contraceptive consisting of spermicide with either condom or diaphragm; Use of intrauterine device with a documented failure rate of \<1% per year; Use of depo provera injection; Male partner who is sterile prior to the female subject's entry into the study and is the sole sexual partner for that female.~* The subject and/or the subject's parent(s)/legal guardian(s) agree to G6PD genotyping in the context of a subsequent hemolytic anemia AE.~* The subject and parent(s)/legal guardian(s) are willing and able to comply with the study protocol.~* In accordance with regional/local laws and regulations, the parent(s)/legal guardian(s) has given written informed, dated consent; and the subject has given written assent, if applicable, to participate in the study.~Exclusion Criteria:~* The subject has a mixed malaria infection (identified by a malarial smear or rapid diagnostic test).~* The subject has a condition that may affect absorption of study medication, such as severe vomiting (no food or inability to take food during the previous 8 hours).~* The subject has a liver alanine aminotransferase (ALT) \>2 time the upper limit of normal (ULN).~* The subject has a clinically significant concurrent illness (for example; pneumonia, meningitis, septicaemia, coagulopathy, severe hemorrhage), pre-existing condition (e.g., renal disease, malignancy, malnutrition, known pre-existing human immunodeficiency virus \[HIV\]), febrile convulsions prior to consent, or clinical signs and symptoms of severe cardiovascular disease (for example; congenital heart disease).~* The subject has a history of porphyria, psoriasis, or epilepsy.~* The subject has taken anti-malarials (for example; artemisinin-based combination therapies, mefloquine, primaquine, or any other 4- or 8-aminoquinoline) or drugs with antimalarial activity within 30 days prior to study entry.~* The subject has received treatment with any investigational drug within 30 days of study entry, or within 5 half-lives, whichever is longer.~* The subject has taken or will likely require during the study the use of: histamine-2 blockers, antacids, anti-diabetic drugs of the biguanide class (i.e., phenformin, buformin), anti-arrhythmic agents dofetilide, procainamide, pilsicainide.~* The subject has a serum creatinine above the ULN and is currently taking metformin.~* The subject has a history of allergy or intolerance to chloroquine, mefloquine, tafenoquine, primaquine, or to any other 4- or 8-aminoquinoline.~* The subject has previously enrolled in this study.~* The subject has severe P. vivax malaria as defined by world health organization (WHO) criteria

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 15 Years
- Healthy Volunteers: f

Study Arms:
- Tafenoquine 50 mg (Type: EXPERIMENTAL): Subjects with weight band of \>=5 to \<=10 kilogram (kg) will receive 50 mg tafenoquine on Day 1. Subject may receive CQ per local/national guidelines.
- Tafenoquine 100 mg (Type: EXPERIMENTAL): Subjects with weight band of \>10 to \<=20 kg will receive 100 mg tafenoquine on Day 1. Subject may receive CQ per local/national guidelines.
- Tafenoquine 150 mg (Type: EXPERIMENTAL): Subjects with weight band of \>10 to \<=20 kg will receive 150 mg tafenoquine on Day 1. Subject may receive CQ per local/national guidelines.
- Tafenoquine 200 mg (Type: EXPERIMENTAL): Subjects with weight band of \>20 to \<=35 kg will receive 200 mg tafenoquine on Day 1. Subject may receive CQ per local/national guidelines.
- Tafenoquine 300 mg (Type: EXPERIMENTAL): Subjects with weight band of \>35 kg will receive 300 mg tafenoquine on Day 1. Subject may receive CQ per local/national guidelines.

Based on this trial design, predict the completion outcome and termination type (if applicable).